Second-line therapy for previously ChT-treated, PD-L1 inhibitor-naïve mNSCLCs, irrespective of tumor PD-L1 expression, is monotherapy ICIs with Nivolumab [45,46], Atezolizumab [47], and Pembrolizumab (only in PD-L1 ≥ 1%) [48], as the OS benefit was irrefutably evidenced. This evidence concerns the gene CD274 and neoplasm.